Azor is a prescription pill that combines two active ingredients-olmesartan and amlodipine. It belongs to the “Heart & Blood Pressure” therapeutic category and is available in a fixed-dose tablet containing 20 mg of olmesartan and 5 mg of amlodipine. In Hong Kong, Azor is classified as a prescription-only medication and is regulated by the Department of Health’s Pharmacy and Poisons Board.
Azor is FDA- and EMA-approved for the treatment of essential (primary) hypertension when monotherapy with either component alone does not achieve target blood-pressure goals. It is indicated for adult patients who require a combination of an ARB and a calcium-channel blocker to reach optimal control. In Hong Kong, the same indication applies under local prescribing guidelines.
Current peer-reviewed evidence does not support routine off-label use of Azor for conditions such as heart failure, chronic kidney disease, or migraine prophylaxis. Any consideration of off-label applications should be made only under direct supervision of a qualified healthcare professional, with a clear discussion of potential risks and benefits.
These reactions are generally mild and often improve with continued therapy or dose adjustment.
Patients should report new swelling, severe dizziness, or signs of angio-edema promptly.
This article provides educational information about Azor and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Azor delivers a fixed 20 mg/5 mg combination in a single tablet, improving adherence by reducing pill burden. The pharmacodynamic synergy of the two agents offers more consistent blood-pressure control than either drug alone, especially in patients who need both mechanisms.
Mild to moderate hepatic impairment requires careful monitoring, but the medication is not outright contraindicated. Severe liver disease (Child-Pugh C) is a contraindication. Your physician will assess liver function tests before prescribing.
Yes, as long as you carry the prescription label and keep the tablets in their original container. Check the destination country’s import rules for prescription medicines; Hong Kong travelers typically need to declare medications exceeding a 30-day supply.
Initial reductions may be observed within a week, but the full antihypertensive effect often requires 4-6 weeks of consistent dosing. Regular monitoring helps determine when the target blood pressure is reached.
Most second-generation antihistamines (e.g., cetirizine, loratadine) have no clinically significant interaction with Azor. However, nasal decongestants containing pseudoephedrine can raise blood pressure and should be used with caution.
Transitioning is usually safe, but your doctor may adjust the dosage based on previous therapy to avoid excessive blood-pressure lowering. A brief overlap or temporary dose reduction may be recommended.
Peripheral edema is a common side effect of amlodipine. Inform your healthcare provider; they may reduce the amlodipine dose, add a diuretic, or consider an alternative regimen.
Yes, receiving the influenza vaccine does not interfere with Azor’s efficacy or safety. Continue your antihypertensive therapy as prescribed.
Because olmesartan influences the renin-angiotensin system, regular checks of serum creatinine and potassium are advised, especially if you have chronic kidney disease or are taking diuretics.
Adopting a low-sodium diet, regular aerobic exercise, moderate alcohol consumption, and maintaining a healthy weight can amplify blood-pressure control and may reduce the need for dose escalation.
